Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 23, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares and American Depositary Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transactions and trust activities rather than consolidated financial performance.
Material Changes and Transactions
The following transactions were reported on March 22 and 23, 2007:
- March 22, 2007: The GSK Trust transferred 4,736 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- March 22, 2007: The GSK US Trust transferred 25 ADRs to participants in the GlaxoSmithKline Performance Share Plan.
- March 23, 2007: The GSK US Trust sold 2,043 ADRs at a price of $55.64 per ADR on behalf of Performance Share Plan participants.
- March 23, 2007: The GSK US Trust transferred 4,422 ADRs to participants in the GlaxoSmithKline Performance Share Plan.
Management Commentary and Risks
The filing details the structure of the GSK Trust (a discretionary trust for employees/former employees) and the GSK US Trust (a grantor trust for SmithKline Beecham Corporation employees/former employees). It notes that Directors Dr. J-P Garnier, Dr. M M Slaoui, and Mr. J S Heslop hold interests in the GSK Trust, while Dr. J-P Garnier and Dr. M M Slaoui hold interests in the GSK US Trust, in the same capacity as other employees. No specific risks, contingencies, or unusual items regarding the company's operations were disclosed in this text.
Investor Verification Points
- Verify the total number of shares and ADRs held by the GSK Trust and GSK US Trust to assess potential dilution or voting power changes.
- Confirm the specific terms of the SmithKline Beecham Employee Share Option Plan 1991 and the GlaxoSmithKline Performance Share Plan.
- Review the aggregate impact of the 2,043 ADR sales at $55.64 on the company's treasury stock or employee compensation liabilities.